CORTCorcept TherapeuticsFinished
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
Cushing Syndrome
4Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.4
3 insiders sold shares within a month
Since Aug 26, 2026 · was worth 10, fading over time
Worry score4
Score over time
- Stage
- Phase 3
- Patients
- 152 (final count)
- Started
- Nov 15, 2018
- Main results expected
- Apr 8, 2024
- Fully finished
- Apr 15, 2024
- Results posted
- Apr 24, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Patients With Loss of Response With Respect to Hypertension During the RW Phase.
Measured over: Week 22 (end of OL Phase) and Week 36 (Week 12 of RW Phase)
Number of Patients With 1 or More Treatment-emergent Adverse Events (TEAEs) as Graded by CTCAE v5.0.
Measured over: OL Phase: Up to 22 weeks; RW Phase: up to 18 weeks after completion of the OL Phase
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 4.4, since 2026-08-26, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03697109 · record last updated 2025-07-16 · checked 2026-11-09 15:42 UTC